Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-01-04
2011-01-04
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S279000
Reexamination Certificate
active
07863278
ABSTRACT:
Disclosed are polymorphs of the isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.
REFERENCES:
patent: 6720332 (2004-04-01), Dickerson et al.
patent: 6936612 (2005-08-01), Barvian et al.
patent: 7189712 (2007-03-01), Brown et al.
patent: 7279473 (2007-10-01), Badiang et al.
patent: 7507834 (2009-03-01), Tang
patent: 2004/0236084 (2004-11-01), Biwersi et al.
patent: 2006/0293338 (2006-12-01), Hasegawa et al.
patent: WO 03/062236 (2003-07-01), None
Sicinski, BBC News/Health, Killer Breast Cancer Therapy Hope, Jan. 21, 2006.
Rane, et al., Nature America, 22, pp. 44-52, May 1999.
Modiano, et al., J. Immuno., 2000, pp. 6693-6702.
Wolf, Kidney Intern'l., vol. 58, Suppl. 77 (2000), pp. S-59-S-66.
Liu, Rong, ed., Water-Insol. Drug Formul. (CRC Press, 2008) Ch. 15, pp. 417-435.
Bastin et al., Org. Process Res. & Develop. 2000, 4, 427-435.
Morris, et al., Intern'l. J. Pharma. 105 (1994) 209-217.
Adeyeye, Moji, ed., Preformulation in Solid Dosage Form Development (Informa Healthcare, 2008) Ch. 2.3, pp. 63-80.
Gould, Intern'l J. Therap. 33, 201 (1986).
Serajuddin, Advan. Drug Deliv. Rev. 59 (2007) 603-616.
Swarbrick et al., eds., Encyclopedia of Pharm. Tech. 13 (Marcel Dekker, NY 1996) pp. 453-499.
Blain, S., et al., “Differential Interaction of the Cyclin-Dependent Kinase (Cdk) Inhibitor p27Kip1with Cyclin A-Cdk2 and Cyclin D2-Cdk4,”The Journal of Biological Chemistry, 1997, 25863-25872, vol. 272, No. 41.
Fischer, P., et al., “Recent Advances And New Directions In The Discovery And Development Of Cyclin-Dependent Kinase Inhbitors,”Current Opinion in Drug Discovery, 2001, 623-634, vol. 4.
Fry, D., et al., “Inhibitors Of cyclin-Dependent Kinases As Therapeutic Agents For The Treatment Of Cancer,”Current Opinion In Oncologic, Endocrine&Metabolic InvestigationalDrugs, 2000, 40-59, vol. 2, No. 1.
“Killer Breast Cancer Therapy Hope,” BBC News/Health, http:/
ews.bbc.co.uk/go/pr/fr/˜/1/hi/health/4619900.stm, Jan. 21, 2006.
Ministerial Order for Lebanese Patent No. 6633, Official Gazette No. 28, Jun. 19, 2003, 4382-4383.
Rane, S., et al., “Loss of Cdk4 Expression Causes Insulin-Deficient Diabetes and Cdk4 Activation Results in β-islet Cell Hyperplasia,”Nature Genetics, 1999, 44-52, vol. 22.
Sielecki, T., et al., “Cyclin-Dependent Kinase Inhibitors: Useful Targets In Cell Cycle Regulation,”Journal of Medicinal Chemistry, 2000, 1-18, vol. 43, No. 1.
Webster, K., et al., “Novel Drugs Targeting The Cell Cycle,”Emerging Drugs, 2000,45-59, vol. 5, No. 1.
Beylin Vladimir Genukh
Blackburn Anthony Clyde
Erdman David Thomas
Toogood Peter Laurence
Hutchinson Keith D.
Jaisle Cecilia M
Tidwell Jeffrey H.
Warner-Lambert CompanyLLC
Wilson James O
LandOfFree
Isethionate salt of a selective CDK4 inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isethionate salt of a selective CDK4 inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isethionate salt of a selective CDK4 inhibitor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2741923